Frontlight ResearchEarly access
What researchers published on Myelodysplastic syndromes
3,116 papers, newest first.
Showing 80 of 3,116
Fever of Unknown Origin in Myelodysplastic Syndrome: Clinical and Laboratory Features of a Chinese Cohort.Journal of clinical medicine
Optimizing Reduced-Intensity Conditioning for Older Patients with AML and MDS: A Large-Scale Analysis from the CIBMTR.Blood
Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS.Blood
Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia.Haematologica
Exploring neuropsychological alterations in VEXAS syndrome.Clinical and experimental medicine
Case reportMyelodysplastic Syndrome With Isolated del(5q) Coexisting With Cold Agglutinin Disease Presenting as Unexplained Hyperbilirubinemia.Cureus
Development and validation of a baseline interpretable prognostic model for mortality risk stratification in myelodysplastic syndrome patients receiving hypomethylating agent therapy.Current problems in cancer
MicroRNA dysregulation in mesenchymal stromal cells in myelodysplastic syndromes and its modulation by azacitidine and bortezomib.Leukemia & lymphoma
ReviewSGLT2 Inhibitors and Hemoglobin Improvement in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Mechanistic Rationale and Emerging Clinical Evidence.Anemia
Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells.Leukemia
Integrating functional marrow reserve and molecular risk improves prediction of post-transplant outcomes in HMA-treated myelodysplastic syndromes.Blood neoplasia
PreprintPersistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms.bioRxiv : the preprint server for biology
Luspatercept in Myelodysplastic Syndromes With Ring Sideroblasts: Long Term Outcome and Impact on Non-Erythroid Blood Counts.Hematological oncology
Impact of Venetoclax Bridging on Haematopoietic Stem Cell Transplantation Outcomes in Advanced Myelodysplastic Neoplasms.Transplantation and cellular therapy
NUDT21 knockdown modulates alternative polyadenylation and promotes leukemic transformation in myelodysplastic syndromes.Neoplasma
Molecular and clinical profiling of SF3B1, U2AF1, and SRSF2 mutations in Iranian patients with myelodysplastic neoplasms.Molecular biology reports
Frontline isocitrate dehydrogenase inhibitor therapy in isocitrate dehydrogenase-mutated myelodysplastic neoplasms.Haematologica
Prevalence and prognostic implications of systemic autoinflammatory and autoimmune diseases in myelodysplastic neoplasms: a retrospective Belgian cohort study.Clinical and experimental medicine
GATA2 Deficiency Presenting With a WHIM-Like Phenotype and Subsequent Development of Monosomy 7-Associated Myelodysplastic Syndrome in an Adolescent Female: A Case Report.Clinical case reports
Review[Hematological features and advancement in the diagnosis of VEXAS syndrome].Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Willingness to Pay for Temporary Transfusion Independence in Lower-Risk Myelodysplastic Syndromes: Evidence from a Cross-Sectional Study in China.Patient preference and adherence
Complement deposition in the bone marrow of patients with myelodysplastic neoplasms.Signal transduction and targeted therapy
Can we better evaluate responses in higher-risk myelodysplastic syndromes?Haematologica
Infectious burden and cellular immune impairment in higher-risk myelodysplastic syndromes with biallelic TP53 alterations.Frontiers in cellular and infection microbiology
Review[Advances in the management of myelodysplastic neoplasms].[Rinsho ketsueki] The Japanese journal of clinical hematology
Case reportPearls & Oy-sters: Beyond the Bone Marrow-VEXAS Syndrome Presenting as Subacute Encephalomyelitis.Neurology
A Novel Insight Into Luspatercept: Therapeutic Implications in Myelodysplastic Syndrome Patients With Elevated Pulmonary Artery Systolic Pressure.Pulmonary circulation
IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC).Transplantation and cellular therapy
Comparison of Fludarabine/Treosulfan Conditioning with Melphalan-Based Sequential Conditioning in Patients with MDS and Increased Blasts Undergoing Upfront Transplantation.Cancers
ReviewDiagnostic and Clinical Considerations in Myeloid Neoplasms with del(5q): Distinguishing Myelodysplastic Neoplasm with Low Blasts and del(5q) from Myeloid Neoplasms with del(5q) Post-Cytotoxic Therapy.Genes
Correction: Balaian et al. Systemic Metabolic Changes in Plasma of Patients with Myelodysplastic Neoplasms and Chronic Myelomonocytic Leukemia. Metabolites 2026, 16, 648.Metabolites
Inflammasome activation promotes the progression of myelodysplastic syndrome.Experimental hematology
Post-transplant monitoring of NGS-based measurable residual disease and donor chimerism as a prognostic tool in older patients with AML/MDS.Blood research
ReviewClinical applications of CD34+ progenitor cell immunophenotyping in myelodysplastic neoplasms-The CytHem SMD French network experience.Cytometry. Part B, Clinical cytometry
PreprintMulti-hit STAG2 mutations define a high-risk subset of MDS and reveal convergent evolutionary targeting of cohesin.bioRxiv : the preprint server for biology
From ribosomal stress to clonal adaptation: Del(5q) MDS as a paradigmatic acquired ribosomopathy.Seminars in hematology
Patient-derived neomorphic SEPTIN6 mutations induce hematopoietic stem cell senescence underlying congenital neutropenia and myelodysplasia.JCI insight
A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome.Clinical immunology (Orlando, Fla.)
A comparison of overall survival and quality of life in patients with MDS treated with azacytidine vs decitabine.Blood neoplasia
Venetoclax plus hypomethylating agent improves response rates but not survival in TP53-mutated myelodysplastic syndromes.Blood neoplasia
Case reportA rare case of acute basophilic leukemia transformed from high risk myelodysplastic syndrome.Annals of hematology
ReviewPersonalized allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes: Integrating molecular risk, donor selection, and post-transplant strategies.Cell transplantation
Venetoclax-based combinations in high-risk myelodysplastic syndromes: highlights from ASH 2025 & EHA 2026.Experimental hematology & oncology
Review[Recommendations of the Groupe Francophone des Myélodysplasies (GFM) - Diagnostic approach and management of myelodysplastic syndromes, chronic myelomonocytic leukemias, and VEXAS syndrome].Bulletin du cancer
Association between chronic kidney disease and the risk of myelodysplastic syndromes: A large claims database study in Japan.British journal of haematology
Financial burden to patients and informal carers of myelodysplastic syndromes in England: a modelled analysis stratified by transfusion dependence.Leukemia research
Synchronous myelodysplastic syndrome and multiple myeloma: a DDX41-associated double-hit across two lineages.Archives of medical science : AMS
Perspectives on FDA Guidance for Myelodysplastic Syndromes.Blood advances
A Stem Cell-based Flow Cytometry Assay to Predict Post-transplantation Relapse in Patients With Myelodysplastic Syndromes With Excess Blasts: A Prospective Study.Transplantation and cellular therapy
ReviewOncostatin M deficiency: A newly recognized inherited bone marrow failure syndrome with potential predisposition to myeloid malignancy.Hematology/oncology and stem cell therapy
Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival.Blood
Case reportAortic-renal aneurysm in a patient with VEXAS syndrome treated with Tocilizumab.ARP rheumatology
Case reportDe novo development of JAK2V617F-positive polycythemia vera following allogeneic hematopoietic stem cell transplantation: a report of two rare cases.Upsala journal of medical sciences
Case reportClinical Images: Collapsing auricles and airways in relapsing polychondritis with myelodysplastic syndrome.ACR open rheumatology
Recurrent Invasive Staphylococcus aureus Infections in a Non-Neutropenic Hemodialysis Patient With Myelodysplastic Syndrome: A Case Report.Case reports in nephrology
Case report[Gecacitinib as a bridging treatment to allogeneic hematopoietic stem cell transplantation for high-risk myelodysplastic syndrome with Behçet's syndrome: a case report].Zhonghua nei ke za zhi
A randomized comparison of CPX-351 and FLAG-Ida in high-risk myelodysplastic syndrome: A subgroup analysis of UK NCRI AML19.Leukemia research reports
Economic Burden of treated Lower-Risk Myelodysplastic Syndromes in France: A Population-Based Study.ClinicoEconomics and outcomes research : CEOR
[Mutation characteristics and prognosis of SF3B1-mutated myeloid neoplasms: an analysis of 183 patients].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Banding Karyotyping From Peripheral Blood Is a Useful Method for the Diagnostic Workup of Myelodysplastic Neoplasia and CMML.Genes, chromosomes & cancer
Case reportMyelodysplastic Syndromes-Transformed Acute Myeloid Leukemia With Concurrent DEK::CAN Fusion Gene Positivity and WT1 Overexpression: A Case Report and Literature Review.Cancer reports (Hoboken, N.J.)
Case reportSF3B1-mutated MDS coexisting with β-thalassemia trait: A case report and literature review focused on diagnostic distinction from acquired β-thalassemia.Medicine
Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study.Leukemia
Clinical Characteristics, Co-Mutations, and Prognostic Factors of TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndrome.Clinical laboratory
Long-read sequencing and the boundary conditions for multi-hit reassurance in TP53-mutated myelodysplastic syndrome. Comment on: "Long-read sequencing resolves TP53 allelic status in myeloid neoplasms".Haematologica
Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial.Haematologica
ReviewMyelodysplastic syndromes/neoplasms presenting with isolated thrombocytopenia: a poorly understood pathophysiology, difficult to diagnose, and challenging to treat entity.Expert review of anticancer therapy
ReviewUBA1 as a proteostasis-innate immunity checkpoint: lessons from vexas syndrome and therapeutic implications.Frontiers in immunology
Choice of a different donor reduces relapse risk after second allogeneic SCT for MDS.Blood
Correction: spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.Leukemia
Preemptive and Therapeutic Donor Lymphocyte Infusion for Acute Leukemia or Myelodysplastic Syndromes: A Real-World Single-Center Study.Transplantation and cellular therapy
Oral Versus Intravenous Hypomethylating Agents in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multicenter Real-World Toxicity Comparison.Acta haematologica
ReviewInterest of luspatercept in treatment of anemia in lower-risk of myelodysplastic syndrome anemia: a single center study of 26 patients.Blood research
Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.Leukemia
Auto-immune diseases associated with myelodysplastic syndrome and chronic myelomonocytic leukemia do not impact allogenic transplantation outcomes.Bone marrow transplantation
CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.Blood neoplasia
Case reportEarly-onset VEXAS syndrome mimicking orbital cellulitis and successfully treated with allogeneic hematopoietic stem cell transplantation.Journal of hematopathology
Menin inhibition in pediatric UBTF-TD myelodysplastic syndrome: molecular rationale and clinical observation.Molecular and cellular pediatrics
Trial resultPhase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.Cancer
In plain wordsRead moreRead the paper on PubMedIncreased glioblastoma risk in patients with myeloproliferative neoplasms and myelodysplastic syndromes.Clinical and experimental medicine